Search

Your search keyword '"Croke, CT"' showing total 4 results
Start Over Author "Croke, CT"
4 results on '"Croke, CT"'

1. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

Author

Andreyev, HJN Norman, AR Cunningham, D Oates, J Dix, BR and Iacopetta, BJ Young, J Walsh, T Ward, R Hawkins, N and Beranek, M Jandik, P Benamouzig, R Jullian, E and Laurent-Puig, P Olschwang, S Muller, O Hoffmann, I and Rabes, HM Zietz, C Troungos, C Valavanis, C Yuen, ST and Ho, JWC Croke, CT O'Donoghue, DP Giaretti, W Rapallo, A and Russo, A Bazan, V Tanaka, M Omura, K Azuma, T and Ohkusa, T Fujimori, T Ono, Y Pauly, M Faber, C and Glaesener, R de Goeij, AFPM Arends, JW Andersen, SN and Lovig, T Breivik, J Gaudernack, G Clausen, OPF De Angelis, P Meling, GI Rognum, TO Smith, R Goh, HS and Font, A Rosell, R Sun, XF Zhang, H Benhattar, J and Losi, L Lee, JQ Wang, ST Clarke, PA Bell, S Quirke, P Bubb, VJ Piris, J Cruickshank, NR Morton, D Fox, JC Al-Mulla, F Lees, N Hall, CN Snary, D Wilkinson, K Dillon, D Costa, J Pricolo, VE Finkelstein, SD and Thebo, JS Senagore, AJ Halter, SA Wadler, S Malik, S and Krtolica, K Urosevic, N

Abstract

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival. P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. (C) 2001 Cancer Research Campaign.

Published
2001

2. Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study

Author

Andreyev, HJN, Norman, AR, Cunningham, D, Oates, J, Dix, BR, Iacopetta, BJ, Young, J, Walsh, T, Ward, R, Hawkins, N, Beranek, M, Jandik, P, Benamouzig, R, Jullian, E, Laurent-Puig, P, Olschwang, S, Muller, O, Hoffmann, I, Rabes, HM, Zietz, C, Troungos, C, Valavanis, C, Yuen, ST, Ho, JWC, Croke, CT, O'Donoghue, DP, Giaretti, W, Rapallo, A, Russo, A, Bazan, V, Tanaka, M, Omura, K, Azuma, T, Ohkusa, T, Fujimori, T, Ono, Y, Pauly, M, Faber, C, Glaesener, R, de Goeij, AFPM, Arends, JW, Andersen, SN, Lovig, T, Breivik, J, Gaudernack, G, Clausen, OPF, De Angelis, P, Meling, GI, Rognum, TO, Smith, R, Goh, HS, Font, A, Rosell, R, Sun, XF, Zhang, H, Benhattar, J, Losi, L, Lee, JQ, Wang, ST, Clarke, PA, Bell, S, Quirke, P, Bubb, VJ, Piris, J, Cruickshank, NR, Morton, D, Fox, JC, Al-Mulla, F, Lees, N, Hall, CN, Snary, D, Wilkinson, K, Dillon, D, Costa, J, Pricolo, VE, Finkelstein, SD, Thebo, JS, Senagore, AJ, Halter, SA, Wadler, S, Malik, S, Krtolica-Žikić, Koviljka, Urosevic, N, Andreyev, HJN, Norman, AR, Cunningham, D, Oates, J, Dix, BR, Iacopetta, BJ, Young, J, Walsh, T, Ward, R, Hawkins, N, Beranek, M, Jandik, P, Benamouzig, R, Jullian, E, Laurent-Puig, P, Olschwang, S, Muller, O, Hoffmann, I, Rabes, HM, Zietz, C, Troungos, C, Valavanis, C, Yuen, ST, Ho, JWC, Croke, CT, O'Donoghue, DP, Giaretti, W, Rapallo, A, Russo, A, Bazan, V, Tanaka, M, Omura, K, Azuma, T, Ohkusa, T, Fujimori, T, Ono, Y, Pauly, M, Faber, C, Glaesener, R, de Goeij, AFPM, Arends, JW, Andersen, SN, Lovig, T, Breivik, J, Gaudernack, G, Clausen, OPF, De Angelis, P, Meling, GI, Rognum, TO, Smith, R, Goh, HS, Font, A, Rosell, R, Sun, XF, Zhang, H, Benhattar, J, Losi, L, Lee, JQ, Wang, ST, Clarke, PA, Bell, S, Quirke, P, Bubb, VJ, Piris, J, Cruickshank, NR, Morton, D, Fox, JC, Al-Mulla, F, Lees, N, Hall, CN, Snary, D, Wilkinson, K, Dillon, D, Costa, J, Pricolo, VE, Finkelstein, SD, Thebo, JS, Senagore, AJ, Halter, SA, Wadler, S, Malik, S, Krtolica-Žikić, Koviljka, and Urosevic, N

Abstract

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes C cancers (failure-free survival. P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. (C) 2001 Cancer Research Campaign.

Published
2001

3. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

Author

J. Breivik, E. Jullian, Nicholas J. Hawkins, S. A. Halter, J. S. Thebo, Viviana Bazan, C. Troungos, Deborah A. Dillon, R. Glaesener, P.M. De Angelis, C. Valavanis, J. C. Fox, R. Smith, C. Faber, Y. Ono, K. Wilkinson, Hong Zhang, Jenq Chang Lee, N. Urosevic, Vivien J. Bubb, K. Krtolica, Jacqui Oates, Pierre Laurent-Puig, Toshifumi Ohkusa, Takahiro Fujimori, D. P. O'Donoghue, K. Omura, Paul A. Clarke, Ingrid Hoffmann, A. R. Norman, M. Pauly, Jose Costa, S T Yuen, David Cunningham, H S Goh, V. E. Pricolo, Sandra M. Bell, Shan Tair Wang, Anthony J. Senagore, Oliver Müller, N. R. Cruickshank, P. Jandik, Jwc Ho, M. Tanaka, G. I. Meling, T. O. Rognum, S Malik, Walter Giaretti, J. Piris, Robyn L. Ward, A. Rapallo, H. M. Rabes, A. Font, N. Lees, C. N. Hall, C. T. Croke, S. N. Andersen, Robert Benamouzig, Rafael Rosell, Jan-Willem Arends, S. Wadler, T. Azuma, S. D. Finkelstein, D. Snary, Barry Iacopetta, Dion Morton, Sylviane Olschwang, Fahd Al-Mulla, Gustav Gaudernack, Antonio Russo, C. Zietz, Xiao-Feng Sun, H J N Andreyev, T. Walsh, Philip Quirke, T. Lovig, M. Beranek, B. R. Dix, J. Young, Ole Petter F. Clausen, L. Losi, A.F.P.M. de Goeij, J. Benhattar, Andreyev, HJN, Norman, AR, Cunningham, D, Oates, J, Dix, BR, Iacopetta, BJ, Young, J, Walsh, T, Ward, R, Hawkins, N, Beranek, M, Jandik, P, Benamouzig, R, Jullian, E, Laurent-Puig, P, Olschwang, S, Muller, O, Hoffmann, I, Rabes, HM, Zietz, C, Troungos, C, Valavanis, C, Yuen, ST, Ho, JWC, Croke, CT, O’Donoghue, DP, Giaretti, W, Rapallo, A, Russo, A, Bazan, V, Tanaka, M, Omura, K, Azuma, T, Ohkusa, T, Fujimori, T, Ono, Y, Pauly, M, FabeR, C, Glaesener, R, de Goeij, AFPM, Arends, JW, Andersen, SN, Lövig, T, Breivik, J, Gaudernack, G, Clausen, OPF, De Angelis, P, Meling, GI, Rognum, TO, Smith, R, Goh, H-S, Font, A, Rosell, R, Sun, XF, Zhang, H, Benhattar, J, Losi, L, Lee, JQ, Wang, ST, Clarke, PA, Bell, S, Quirke, P, Bubb, VJ, Piris, J, Cruickshank,NR, Morton, D, Fox, JC, Al-Mulla, F, Lees, N, Hall, CN, Snary, D, K Wilkinson, VJ, Dillon, D, Costa, J, Pricolo, VE, Finkelstein, SD, Thebo, JS, Senagore, AJ, Halter, SA, Wadler, S, Malik, S, Krtolica, K, and Urosevic, N

Subjects
Male, Oncology, Cancer Research, Pathology, Multivariate analysis, Databases, Factual, Settore MED/06 - Oncologia Medica, Colorectal cancer, Gene mutation, medicine.disease_cause, 0302 clinical medicine, Genotype, Colorectal cancer, Ki-ras, mutation, Registries, Aged, 80 and over, 0303 health sciences, Mutation, Valine, Middle Aged, 3. Good health, KRAS Mutation Analysis, medicine.anatomical_structure, Presented by the Kirsten ras in-colorectal-cancer collaborative group, 030220 oncology & carcinogenesis, Female, Colorectal Neoplasms, Adult, medicine.medical_specialty, Adolescent, overall survival, Mutation, Missense, Rectum, colorectal cancer, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Point Mutation, K-ras, Codon, prognosis, Aged, Neoplasm Staging, Proportional Hazards Models, 030304 developmental biology, business.industry, Cancer, medicine.disease, Survival Analysis, Genes, ras, Multivariate Analysis, business
Abstract

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

4. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.

Author

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, and Urosevic N

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Codon genetics, Colorectal Neoplasms mortality, Disease-Free Survival, Female, Genotype, Humans, Male, Middle Aged, Multivariate Analysis, Mutation, Missense, Neoplasm Staging, Proportional Hazards Models, Survival Analysis, Valine genetics, Colorectal Neoplasms genetics, Databases, Factual, Genes, ras genetics, Point Mutation, Registries
Abstract

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes' C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes' B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer., (Copyright 2001 Cancer Research Campaign.)

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results